Biocept (BIOC) to Release Earnings on Monday

Biocept (NASDAQ:BIOC) is scheduled to post its quarterly earnings results after the market closes on Monday, August 12th.

Biocept (NASDAQ:BIOC) last posted its quarterly earnings data on Wednesday, May 8th. The medical research company reported ($0.61) earnings per share (EPS) for the quarter. Biocept had a negative net margin of 695.85% and a negative return on equity of 338.61%. The business had revenue of $1.02 million for the quarter.

BIOC traded down $0.01 during trading hours on Tuesday, reaching $1.01. 975 shares of the company’s stock traded hands, compared to its average volume of 456,919. The company’s 50-day moving average price is $1.05. Biocept has a 52-week low of $0.66 and a 52-week high of $4.75. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.72 and a quick ratio of 2.63. The firm has a market capitalization of $19.16 million, a price-to-earnings ratio of -0.11 and a beta of 1.93.

A number of equities analysts recently issued reports on the company. Maxim Group restated a “buy” rating and set a $3.00 price objective on shares of Biocept in a report on Thursday, May 9th. ValuEngine upgraded Biocept from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

Biocept Company Profile

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

Read More: What is a death cross?

Earnings History for Biocept (NASDAQ:BIOC)

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.